1. Home
  2. ATNM vs IXHL Comparison

ATNM vs IXHL Comparison

Compare ATNM & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.40

Market Cap

50.2M

Sector

Health Care

ML Signal

HOLD

Logo Incannex Healthcare Inc.

IXHL

Incannex Healthcare Inc.

HOLD

Current Price

$0.43

Market Cap

49.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATNM
IXHL
Founded
2000
2001
Country
United States
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.2M
49.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ATNM
IXHL
Price
$1.40
$0.43
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
194.8K
23.8M
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$90,000.00
$12,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$42,943.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
11.11
N/A
52 Week Low
$1.03
$0.08
52 Week High
$2.41
$2.25

Technical Indicators

Market Signals
Indicator
ATNM
IXHL
Relative Strength Index (RSI) 51.02 59.02
Support Level $1.33 $0.35
Resistance Level $1.54 $0.50
Average True Range (ATR) 0.09 0.03
MACD 0.01 0.02
Stochastic Oscillator 56.90 68.63

Price Performance

Historical Comparison
ATNM
IXHL

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Share on Social Networks: